ARTES Biotechnology issued New Patent in Australia for VLP Technology

ARTES Biotech­nol­o­gy spe­cial­ized in micro­bial cell line and process devel­op­ment as well as in tech­nol­o­gy trans­fer for phar­ma­ceu­ti­cal indus­try is pleased to announce the issuance of a new patent for their VLP plat­form. The patent will fur­ther strength­en the Metavax® plat­form of the com­pa­ny. In com­bi­na­tion with the expres­sion plat­form Hansenu­la Metavax® is a unique tool for the devel­op­ment of afford­able, safe and effec­tive vaccines.
“Our intel­lec­tu­al prop­er­ty strat­e­gy is to pro­vide mul­ti­ple lay­ers of pro­tec­tion for our tech­nol­o­gy plat­form port­fo­lio. We believe that this new patent will have addi­tion­al rein­force­ment to our exist­ing patent estate and for our ser­vice we offer clients for vac­cine devel­op­ment,” said Dr. Melanie Pio­ntek, Busi­ness Devel­op­ment Direc­tor of ARTES.